Anesthetic Effect - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 88
Inquire Before Buying

Anesthetic Effect - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H2 2017, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.

Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System)

List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anesthetic Effect (Central Nervous System) pipeline guide

List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 The guide covers therapeutics under Development by Companies /Universities /Institutes,

List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017

Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is

List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Anesthetic Effect - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Anesthetic Effect - Overview
Anesthetic Effect - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anesthetic Effect - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anesthetic Effect - Companies Involved in Therapeutics Development
4P Therapeutics LLC
Biolab Farmaceutica Ltda
Crescita Therapeutics Inc
Drawbridge Pharmaceuticals Pty Ltd
Expanesthetics Inc
Jiangsu Hengrui Medicine Co Ltd
Lee's Pharmaceutical Holdings Ltd
Lipicard Technologies Ltd
Paion AG
Phosphagenics Ltd
Physica Pharma
Primex Pharmaceuticals Oy
Proteus SA
Recro Pharma Inc
Taiwan Liposome Company Ltd
The Medicines Company
Anesthetic Effect - Drug Profiles
alphaxalone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aom-0765 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bupivacaine hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Carboetomidate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cysteine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXPS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXPS-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXPS-09 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Flexicaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gabafol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSK-3486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-1121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-1123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Methoxycarbonyl Carboetomidate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Methoxycarbonyl Etomidate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
midazolam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
neosaxitoxin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-5109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHY-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remimazolam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remimazolam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Anesthetic Effect - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-819 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anesthetic Effect - Dormant Projects
Anesthetic Effect - Discontinued Products
Anesthetic Effect - Product Development Milestones
Featured News & Press Releases
Mar 09, 2017: China FDA has Approved Zingo for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial
Nov 14, 2016: Powder Pharmaceuticals Submits New Drug Application to China FDA and Hong Kong Department of Health for Needle-free Local Analgesia
Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting
Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA
Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015
Sep 01, 2015: Recently Published Study Shows Positive Results for ZiNGO in Pediatric Patients
Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia
Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States
Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Anesthetic Effect, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Anesthetic Effect - Pipeline by 4P Therapeutics LLC, H2 2017
Anesthetic Effect - Pipeline by Biolab Farmaceutica Ltda, H2 2017
Anesthetic Effect - Pipeline by Crescita Therapeutics Inc, H2 2017
Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2017
Anesthetic Effect - Pipeline by Expanesthetics Inc, H2 2017
Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Anesthetic Effect - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017
Anesthetic Effect - Pipeline by Lipicard Technologies Ltd, H2 2017
Anesthetic Effect - Pipeline by Paion AG, H2 2017
Anesthetic Effect - Pipeline by Phosphagenics Ltd, H2 2017
Anesthetic Effect - Pipeline by Physica Pharma, H2 2017
Anesthetic Effect - Pipeline by Primex Pharmaceuticals Oy, H2 2017
Anesthetic Effect - Pipeline by Proteus SA, H2 2017
Anesthetic Effect - Pipeline by Recro Pharma Inc, H2 2017
Anesthetic Effect - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Anesthetic Effect - Pipeline by The Medicines Company, H2 2017
Anesthetic Effect - Dormant Projects, H2 2017
Anesthetic Effect - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Anesthetic Effect, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Global Tissue Expanders Market Research Report 2018
    Published: 12-Jan-2018        Price: US 2900 Onwards        Pages: 113
    In this report, the global Tissue Expanders market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Tissue Expanders in these regions, from 2013 to 2025 (forecast), covering - North America - Europe - China - J......
  • Global Thyroid Gland Disorder Treatment Market Size, Status and Forecast 2025
    Published: 11-Jan-2018        Price: US 3300 Onwards        Pages: 94
    This report studies the global Thyroid Gland Disorder Treatment market, analyzes and researches the Thyroid Gland Disorder Treatment development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Pfizer - Abbott - RLC LABS - Allergan - Merck Sharp & Dohme Market segment by Regions/Countries, this report covers - United States - EU -......
  • Global Peptide Therapeutics Market Research Report 2018
    Published: 11-Jan-2018        Price: US 2900 Onwards        Pages: 104
    In this report, the global Peptide Therapeutics market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Peptide Therapeutics in these regions, from 2013 to 2025 (forecast), covering - North America - Europe - China......
  • Global Human Microbiome Therapeutics Market Research Report 2011-2023
    Published: 09-Jan-2018        Price: US 1910 Onwards        Pages: 90
    Summary The global Human Microbiome Therapeutics market will reach xxx Million USD in 2017 with CAGR xx% 2018-2023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc. Based on products type, the report describes major products type share of regional market. Products men......
  • Global Enzyme Replacement Therapy Market Size, Status and Forecast 2025
    Published: 08-Jan-2018        Price: US 3300 Onwards        Pages: 98
    This report studies the global Enzyme Replacement Therapy market, analyzes and researches the Enzyme Replacement Therapy development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Genzyme Corporation - Shire - Pfizer - BioMarin Pharmaceutical - Sigma-Tau Pharmaceuticals - Essential Pharmaceuticals Limited - Merck Kga - AbbVie Inc ......
  • Global Infantile Spasms Therapeutics Market Research Report 2011-2023
    Published: 04-Jan-2018        Price: US 1870 Onwards        Pages: 89
    Summary An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending for......
  • Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 30
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H2 2017, provides an overview of the Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline landscape. Spinal and bulbar muscular atrophy or Kennedy disease is a disorder of specialized nerve cells that control muscle movement. These nerve cells originate in the spinal cord and the part of the bra......
  • Ornithine-Transcarbamylase Deficiency - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 42
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ornithine-Transcarbamylase Deficiency - Pipeline Review, H2 2017, provides an overview of the Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline landscape. Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder characterized by complete or partial lack of the enzyme ornithine transcarbamylase (OTC). OTC plays an important role in the break down and removal o......
  • Usher Syndrome - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 39
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Usher Syndrome - Pipeline Review, H2 2017, provides an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape. Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs